Healthy individuals can harbour microscopic tumours and dysplastic foci in different organs
in an undetectable and asymptomatic state for many years. These lesions do not progress in …

Colorectal cancer (CRC) is known as the third most common and fourth leading cancer
associated death worldwide. The occurrence of metastasis has remained as a critical …

Background: Combinations of chemotherapy regimens and monoclonal antibodies have
been demonstrated to improve clinical outcomes in patients with metastatic colorectal …

Bevacizumab (Avastin) is a recombinant humanized monoclonal immunoglobulin antibody
that has two antigen-binding domains and blocks all active forms of vascular endothelial …

Purpose: Tivozanib, a selective inhibitor of VEGFR-1,-2, and-3, plus mFOLFOX6 in an
advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity …

Background: Prevention is the primary strategy to avoid the occurrence and mortality of
colorectal cancer. Generally, the concentrations of tumor markers tested during the …

After the approval of bevacizumab for the first-line treatment of metastatic colorectal cancer
(mCRC) in China, published information was still limited. This observational cohort study …

In the past decades, cancer medicine studies have mainly focused on tumor cell biology as
the main promoter of solid tumor progression. However, tumor biology does not explain the …

Introduction This multicenter phase II study determined the efficacy and safety of new daily
oral S-1 and weekly irinotecan (CPT-11) combination schedule in patients with previously …

Background: The present study was aimed to evaluate the efficacy and safety of at least
three cycles of Bevacizumab in combination with chemotherapy regimens, FOLFIRI or …